[{"id":"cb3edfcf-83c1-43e0-b3bf-9c781f80edfd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169178","created_at":"2021-01-18T20:20:27.015Z","updated_at":"2024-07-02T16:36:45.411Z","phase":"Phase 1","brief_title":"Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status","source_id_and_acronym":"NCT04169178","lead_sponsor":"Henlix, Inc","biomarkers":" KRAS • MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression • MET mutation","tags":["KRAS • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLX55"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-05-01"}]